LiBBY Trial Findings for Late-Stage Dementia Agitation in 2026: Why the Findings May Not Change Care Yet for Spouses and Partners

Learn what LiBBY's agitation results mean for late-stage dementia and what spouses can discuss with hospice now.

LiBBY, Life's End Benefits of cannaBidiol and tetrahYdrocannabinol, eased agitation in late-stage dementia but will not change care yet for spouses and partners. The tested THC and CBD oil remains investigational and is not available by prescription.

The study focused on hospice-eligible people with advanced Alzheimer's or other dementia and clinically significant agitation. Agitation means restlessness, vocal outbursts, or resistance to care that distress both patients and families. For partners, the near-term task is steady symptom planning with the existing care team.

Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.

Table of Contents

What LiBBY tested

The trial was an NIH-funded Phase 2 multicenter randomized double-blind placebo-controlled study in 120 hospice-eligible participants. Study visits took place in homes and residences through 10 U.S. centers.

As the Alzheimer's Association reports, topline results were presented at AAIC in London on July 14, 2026 in the Alzheimer's Association release. Participants received either placebo or a standardized oral oil with 2 mg THC plus 100 mg CBD twice daily for 12 weeks. Georgetown University School of Medicine describes it as a medical formulation distinct from dispensary cannabis.

How much agitation changed

Relief appeared early. Treated participants had a 6.27-point greater reduction on the Cohen-Mansfield Agitation Inventory than placebo by Week 2, according to The Educated Patient.

That scale rates how often agitation behaviors occur. Benefit grew through Week 12. At that point, as Pennington Biomedical Research Center reports, the THC and CBD group had an 8.23-point greater reduction and 87.2% showed overall improvement versus 23.6% on placebo in the Pennington trial summary.

What side effects occurred

Overall adverse events were similar, at 46.7% with treatment and 42.4% with placebo. Serious events were higher with treatment, at 23.3% versus 11.9%. Investigators judged none drug-related during the 12 weeks, according to The Educated Patient.

Similar overall rates do not mean low risk. Late-stage dementia brings frailty, falls, infections, and hospital visits that can look like side effects. A larger trial must separate drug effects from background illness.

Why prescriptions cannot change yet

The findings remain early. They come from a small Phase 2 study using an investigational product. Peer review, larger Phase 3 trials, and FDA review are still needed before doctors can prescribe it.

That gap matters for access. Hospice formularies and insurance cannot cover an unapproved study drug. Families cannot take the dose to a pharmacy or hospice nurse yet.

What spouses and partners can do now

Agitation affects about half of people with dementia near the end of life, and current options are limited. As the U.S. FDA notes in the FDA approval notice, brexpiprazole remains the first and only approved drug for agitation in Alzheimer's dementia.

Do not substitute retail cannabis for the study oil. Doses, purity, and interactions differ, and sedation or confusion can raise fall risk. Spouses and partners can prepare for the next visit: Bring that list to the hospice nurse or doctor before changing anything.

  • track when agitation starts, what helps, and what worsens it
  • list sleep, pain, medicines, and recent changes
  • ask the hospice or palliative team about a written agitation plan

You Might Also Like

HelpDementia.com

Dementia, Alzheimer's, Caregiving & Healthy Aging Guidance

© 2026 HelpDementia.com. All rights reserved.

Educational information only. It is not medical advice and does not replace care from a qualified clinician.